Gastroesophageal Reflux Disease Market Trends

Growth Drivers

Growing Cases of Esophageal Diseases – Esophageal diseases are a group of diseases that affects the esophagus, the tube responsible for carrying food from the mouth to the stomach. It causes heat burn during eating and swallowing problems and increases the chances of GERD in a human being.
Surge in Digestive Disorders – Regular drinking habits, lower physical exercise, and rising stress levels among the global population have led to an increase in digestive health disorders. This factor is estimated to fuel the global gastroesophageal reflux disease market size in the future. A report from 2022 stated that nearly 40% of Americans’ daily lives are disrupted by digestive troubles.
High Prevalence of Gastrointestinal (GI) Tract Diseases – Owing to the consumption of an unhealthy amount of junk along with the rising stress, anxiety, and panic levels among the middle age population is anticipated to bring lucrative growth opportunities for market growth in the next few years. It is observed that in the United States, irritable bowel syndrome is common with a prevalence of about 12% to 14%.
Increasing Desire for Eating Unhealthy Food Items – Fast-paced lives have propelled the working population for processed and junk food items owing to their easy availability, convenience, and taste. However, the outcome of eating unhealthy food daily is the development of gastroesophageal reflux disease (GERD). The consumption of ultra-processed food in the United States region has increased from around 54% in 2002 to approximately 57% in 2018.

Challenges

High Cost of the Treatment – GERD is classified as a chronic disease that requires long-term disease management which is costly. Pharmaceutical costs along with the physician and hospital fees, medicine prices, and surgery charges are directly linked with the treatment of gastroesophageal disease. This is estimated to hamper market growth during the forecast period.
Lack of Awareness Regarding the Disease
Unavailability of Qualified Professionals and Supporting Staff

Gastroesophageal Reflux Disease Market: Key Insights

Base Year	2023
Forecast Year	2024-2036
CAGR	2.3%
Base Year Market Size (2023)	USD 5.12 Billion
Forecast Year Market Size (2036)	USD 6.88 Billion
Regional Scope	North America (U.S., and Canada) Latin America (Mexico, Argentina, Rest of Latin America) Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific) Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe) Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of gastroesophageal reflux disease is estimated at USD 5.24 Billion.

The gastroesophageal reflux disease (GERD) market size was over USD 5.12 Billion in 2023 and is anticipated to reach USD 6.88 Billion by 2036, witnessing around 2.3% CAGR during the forecast period i.e., between 2024-2036. Higher consumption of processed food, increase in digestive issues, and problems caused by contaminated food are the few factors likely to propel the market growth.

North America industry is projected to hold 35% of the revenue share in the 2036, owing to rising aging population in the region which are more prone to gastrointestinal problems.

AstraZeneca PLC, Eisai Co., Ltd., GSK plc., Takeda Pharmaceutical Company Limited., Ironwood Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., SFJ Pharmaceuticals, Sebela Pharmaceuticals, Phathom Pharmaceuticals, Inc., Camber Pharmaceuticals, Inc.

Gastroesophageal Reflux Disease Market Trends